Activation of OX40 augments Th17 cytokine expression and antigen-specific uveitis

American Journal of Pathology

Volumn 177, Issue 6, 2010, Pages 2912-2920

  Zhang, Zili ^a,b   Zhong, Wenwei ^a   Hinrichs, David ^c   Wu, Xiumei ^a   Weinberg, Andrew ^d   Hall, Mark ^a   Spencer, Doran ^b   Wegmann, Keith ^c   Rosenbaum, James T ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD134 ANTIGEN; CD40 LIGAND; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 23 RECEPTOR; NEUTRALIZING ANTIBODY; OVALBUMIN; OX40 ACTIVATING ANTIBODY; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH17 CELL; UPREGULATION; UVEITIS;

EID: 78650202203     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.100353     Document Type: Article

References (54)

1. Nussenblatt RB: The natural history of uveitis. Int Ophthalmol 1990, 14:303-308
2. Becker MD, Adamus G, Davey MP, Rosenbaum JT: The role of T cells in autoimmune uveitis. Ocul Immunol Inflamm 2000, 8:93-100
3. Martin TM, Smith JR, Rosenbaum JT: Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies. Curr Opin Rheumatol 2002, 14:337-341
4. Atalla L, Linker-Israeli M, Steinman L, Rao NA: Inhibition of autoimmune uveitis by anti-CD4 antibody. Invest Ophthalmol Vis Sci 1990, 31:1264-1270 (Pubitemid 20212354)
5. Kilmartin DJ, Fletcher ZJ, Almeida JA, Liversidge J, Forrester JV, Dick AD: CD69 expression on peripheral CD4+ T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis. Invest Ophthalmol Vis Sci 2001, 42:1285-1292 (Pubitemid 32381971)
6. Rothova A, Buitenhuis HJ, Meenken C, Brinkman CJ, Linssen A, Alberts C, Luyendijk L, Kijlstra A: Uveitis and systemic disease. Br J Ophthalmol 1992, 76:137-141
7. Yoshimura T, Sonoda KH, Ohguro N, Ohsugi Y, Ishibashi T, Cua DJ, Kobayashi T, Yoshida H, Yoshimura A: Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatol 2009, 48:347-354
8. Liu X, Lee YS, Yu CR, Egwuagu CE: Loss of STAT3 in CD4+ T cells prevents development of experimental autoimmune diseases. J Immunol 2008, 180:6070-6076
9. Zhang Z, Zhong W, Spencer D, Chen H, Lu H, Kawaguchi T, Rosenbaum JT: Interleukin-17 causes neutrophil mediated inflammation in ovalbumin-induced uveitis in DO11.10 mice. Cytokine 2009, 46:79-91
10. Bettelli E, Korn T, Kuchroo VK: Th17: the third member of the effector T cell trilogy. Curr Opin Immunol 2007, 19:652-657 (Pubitemid 350236805)
11. Dong C: TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008, 8:337-348
12. McGeachy MJ, Cua DJ: Th17 cell differentiation: the long and winding road. Immunity 2008, 28:445-453 (Pubitemid 351467042)
13. Ouyang W, Kolls JK, Zheng Y: The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008, 28:454-467
14. Tesmer LA, Lundy SK, Sarkar S, Fox DA: Th17 cells in human disease. Immunol Rev 2008, 223:87-113
15. Abraham C, Cho J: Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis 2009, 15:1090-1100
16. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, Kleinschek MA, Owyang A, Mattson J, Blumenschein W, Murphy E, Sathe M, Cua DJ, Kastelein RA, Rennick D: IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006, 116:1310-1316
17. Luger D, Silver PB, Tang J, Cua D, Chen Z, Iwakura Y, Bowman EP, Sgambellone NM, Chan CC, Caspi RR: Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 2008, 205:799-810
18. Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, Gery I, Lee YS, Egwuagu CE: TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007, 13:711-718 (Pubitemid 46889754)
19. Aujla SJ, Dubin PJ, Kolls JK: Th17 cells and mucosal host defense. Semin Immunol 2007, 19:377-382
20. Acuto O, Michel F: CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol 2003, 3:939-951
21. Redmond WL, Ruby CE, Weinberg AD: The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit Rev Immunol 2009, 29:187-201
22. Sugamura K, Ishii N, Weinberg AD: Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 2004, 4:420-431
23. Weinberg AD: OX40: targeted immunotherapy-implications for tempering autoimmunity and enhancing vaccines. Trends Immunol 2002, 23:102-109
24. Lane P: Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells. J Exp Med 2000, 191:201-206
25. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M: OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001, 15:445-455 (Pubitemid 32907391)
26. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y: IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 2003, 100:5986-5990
27. Croft M, So T, Duan W, Soroosh P: The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev 2009, 229:173-191
28. Huang MC, Liao JJ, Bonasera S, Longo DL, Goetzl EJ: Nuclear factor-kappaB-dependent reversal of aging-induced alterations in T cell cytokines. FASEB J 2008, 22:2142-2150
29. Weinberg AD, Bourdette DN, Sullivan TJ, Lemon M, Wallin JJ, Maziarz R, Davey M, Palida F, Godfrey W, Engleman E, Fulton RJ, Offner H, Vandenbark AA: Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat Med 1996, 2:183-189
30. Nohara C, Akiba H, Nakajima A, Inoue A, Koh CS, Ohshima H, Yagita H, Mizuno Y, Okumura K: Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells. J Immunol 2001, 166:2108-2115
31. Caspi RR, Roberge FG, Chan CC, Wiggert B, Chader GJ, Rozenszajn LA, Lando Z, Nussenblatt RB: A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol 1988, 140:1490-1495
32. Dullforce PA, Seitz GW, Garman KL, Michael JA, Crespo SM, Fleischman RJ, Planck SR, Parker DC, Rosenbaum JT: Antigen-specific accumulation of naive, memory and effector CD4 T cells during anterior uveitis monitored by intravital microscopy. Cell Immunol 2006, 239:49-60
33. Becker MD, Crespo S, Martin TM, Planck SR, Naramura M, Rosenbaum JT: Intraocular in vivo imaging of activated T-lymphocytes expressing green-fluorescent protein after stimulation with endotoxin. Graefes Arch Clin Exp Ophthalmol 2001, 239:609-612
34. Mempel TR, Pittet MJ, Khazaie K, Weninger W, Weissleder R, von Boehmer H, von Andrian UH: Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity 2006, 25:129-141 (Pubitemid 44066829)
35. Peng Y, Han G, Shao H, Wang Y, Kaplan HJ, Sun D: Characterization of IL-17+ interphotoreceptor retinoid-binding protein-specific T cells in experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2007, 48:4153-4161
36. Zhang R, Qian J, Guo J, Yuan YF, Xue K: Suppression of experimental autoimmune uveoretinitis by Anti-IL-17 antibody. Curr Eye Res 2009, 34:297-303
37. Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, Weinberg AD: OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res 2008, 68:5206-5215
38. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, Schluns K, Tian Q, Watowich SS, Jetten AM, Dong C: Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007, 448:480-483
39. McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, McClanahan TK, O'Shea JJ, Cua DJ: The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 2009, 10:314-324
40. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE, Leonard WJ, Littman DR: IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007, 8:967-974
41. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL: Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003, 278:1910-1914 (Pubitemid 36801431)
42. Frucht DM: IL-23: a cytokine that acts on memory T cells. Sci Signal 2002, 114:PE1
43. Huber M, Brüstle A, Reinhard K, Guralnik A, Walter G, Mahiny A, von Löw E, Lohoff M: IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype. Proc Natl Acad Sci USA 2008, 105:20846-20851
44. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Cong C: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141
45. Nurieva RI, Treuting P, Duong J, Flavell RA, Dong C: Inducible costimulator is essential for collagen-induced arthritis. J Clin Invest 2003, 111:701-706
46. Ndhlovu LC, Ishii N, Murata K, Sato T, Sugamura K: Critical involvement of OX40 ligand signals in the T cell priming events during experimental autoimmune encephalomyelitis. J Immunol 2001, 167:2991-2999
47. Carboni S, Aboul-Enein F, Waltzinger C, Killeen N, Lassmann H, Peña-Rossi C: CD134 plays a crucial role in the pathogenesis of EAE and is upregulated in the CNS of patients with multiple sclerosis. J Neuroimmunol 2003, 145:1-11 (Pubitemid 37485962)
48. Arch RH, Thompson CB: 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB. Mol Cell Biol 1998, 18:558-565
49. Kawamata S, Hori T, Imura A, Takaori-Kondo A, Uchiyama T: Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation. J Biol Chem 1998, 273:5808-5814
50. Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski C, Delespesse G: Expression and function of OX40 ligand on human dendritic cells. J Immunol 1997, 159:3838-3848
51. Chen AI, McAdam AJ, Buhlmann JE, Scott S, Lupher ML Jr., Greenfield EA, Baum PR, Fanslow WC, Calderhead DM, Freeman GJ, Sharpe AH: OX40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immunity 1999, 11:689-698
52. Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, Strom TB, Oukka M, Kuchroo VK: IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, 448:484-487 (Pubitemid 47123515)
53. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ: IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240
54. Nakae S, Iwakura Y, Suto H, Galli SJ: Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol 2007, 81:1258-1268